Ludmila Perelygina1, Joseph Icenogle1, Kathleen E Sullivan2. 1. Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. Division of Allergy and Immunology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Abstract
PURPOSE OF THE REVIEW: The aim of this article is to summarize recent data on rubella virus (RuV) vaccine in chronic inflammation focusing on granulomas in individuals with primary immunodeficiencies (PIDs). RECENT FINDINGS: The live attenuated RuV vaccine has been recently associated with cutaneous and visceral granulomas in children with various PIDs. RuV vaccine strain can persist for decades subclinically in currently unknown body site(s) before emerging in granulomas. Histologically, RuV is predominately localized in M2 macrophages in the granuloma centers. Multiple mutations accumulate during persistence resulting in emergence of immunodeficiency-related vaccine-derived rubella viruses (iVDRVs) with altered immunological, replication, and persistence properties. Viral RNA was detected in granuloma biopsies and nasopharyngeal secretions and infectious virus were isolated from the granuloma lesions. The risk of iVDRV transmissibility to contacts needs to be evaluated. Several broad-spectrum antiviral drugs have been tested recently but did not provide significant clinical improvement. Hematopoietic stem cell transplantation remains the only reliable option for curing chronic RuV-associated granulomas in PIDs. SUMMARY: Persistence of vaccine-derived RuVs appears to be a crucial factor in a significant proportion of granulomatous disease in PIDs. RuV testing of granulomas in PID individuals might help with case management.
PURPOSE OF THE REVIEW: The aim of this article is to summarize recent data on rubella virus (RuV) vaccine in chronic inflammation focusing on granulomas in individuals with primary immunodeficiencies (PIDs). RECENT FINDINGS: The live attenuated RuV vaccine has been recently associated with cutaneous and visceral granulomas in children with various PIDs. RuV vaccine strain can persist for decades subclinically in currently unknown body site(s) before emerging in granulomas. Histologically, RuV is predominately localized in M2 macrophages in the granuloma centers. Multiple mutations accumulate during persistence resulting in emergence of immunodeficiency-related vaccine-derived rubella viruses (iVDRVs) with altered immunological, replication, and persistence properties. Viral RNA was detected in granuloma biopsies and nasopharyngeal secretions and infectious virus were isolated from the granuloma lesions. The risk of iVDRV transmissibility to contacts needs to be evaluated. Several broad-spectrum antiviral drugs have been tested recently but did not provide significant clinical improvement. Hematopoietic stem cell transplantation remains the only reliable option for curing chronic RuV-associated granulomas in PIDs. SUMMARY: Persistence of vaccine-derived RuVs appears to be a crucial factor in a significant proportion of granulomatous disease in PIDs. RuV testing of granulomas in PID individuals might help with case management.
Authors: Ludmila Perelygina; Stanley Plotkin; Pierre Russo; Timo Hautala; Francisco Bonilla; Hans D Ochs; Avni Joshi; John Routes; Kiran Patel; Claudia Wehr; Joseph Icenogle; Kathleen E Sullivan Journal: J Allergy Clin Immunol Date: 2016-09-06 Impact factor: 10.793
Authors: Saul Oswaldo Lugo-Reyes; Nina Pastor; Edith González-Serrano; Marco Antonio Yamazaki-Nakashimada; Selma Scheffler-Mendoza; Laura Berron-Ruiz; Guillermo Wakida; Maria Enriqueta Nuñez-Nuñez; Ana Paola Macias-Robles; Aide Tamara Staines-Boone; Edna Venegas-Montoya; Carmen Alaez-Verson; Carolina Molina-Garay; Luis Leonardo Flores-Lagunes; Karol Carrillo-Sanchez; Julie Niemela; Sergio D Rosenzweig; Paul Gaytan; Jorge A Yañez; Ivan Martinez-Duncker; Luigi D Notarangelo; Sara Espinosa-Padilla; Mario Ernesto Cruz-Munoz Journal: J Clin Immunol Date: 2021-05-05 Impact factor: 8.317
Authors: Ludmila Perelygina; Raeesa Faisthalab; Emily Abernathy; Min-Hsin Chen; LiJuan Hao; Lionel Bercovitch; Diana K Bayer; Lenora M Noroski; Michael T Lam; Maria Pia Cicalese; Waleed Al-Herz; Arti Nanda; Joud Hajjar; Koen Vanden Driessche; Shari Schroven; Julie Leysen; Misha Rosenbach; Philipp Peters; Johannes Raedler; Michael H Albert; Roshini S Abraham; Hemalatha G Rangarjan; David Buchbinder; Lisa Kobrynski; Anne Pham-Huy; Julie Dhossche; Charlotte Cunningham Rundles; Anna K Meyer; Amy Theos; T Prescott Atkinson; Amy Musiek; Mehdi Adeli; Ute Derichs; Christoph Walz; Renate Krüger; Horst von Bernuth; Christoph Klein; Joseph Icenogle; Fabian Hauck; Kathleen E Sullivan Journal: Front Immunol Date: 2021-12-20 Impact factor: 7.561
Authors: Ulrich Baumann; Johannes H Schulte; Jonathan P Groß; Rita Beier; Marius Ludwig; Volker Wahn; Jörg Hofmann; Britta Maecker-Kolhoff; Martin Sauer; Petra Kaiser-Labusch; Negin Karimian; Ulrike Blume-Peytavi; Franziska Ghoreschi; Hagen Ott; Ludmila Perelygina; Christian Klemann; Oliver Blankenstein; Horst von Bernuth; Renate Krüger Journal: Front Immunol Date: 2022-06-02 Impact factor: 8.786